

Table 6. Comparison of the clinical characteristics between the groups with and without HF-related events in HFpEF patients

	Without HF-related events group (n = 329)	With HF-related events group (n = 168)	P value
The modified H ₂ FPEF score	4.92±2.10	6.56±1.91	0.149
Age (years)	67.82±10.38	71.48±10.23*	0.741
Female (%)	179 (54.4)	109 (64.9)	0.025
BMI (kg/m ²)	25.72±3.51	26.53±3.62	0.743
SBP (mm Hg)	134.68±20.24	136.52±21.80	0.141
DBP (mm Hg)	79.26±12.99	78.56±13.23	0.896
Heart rate	82.39±27.09	83.74±23.62	0.159
Smoking (%)	59 (17.9)	16 (9.5)	0.013
Hypertension (%)	230 (69.9)	128 (76.2)	0.140
Diabetes (%)	79 (24.0)	44 (26.2)	0.595
Atrial fibrillation (%)	150 (45.6)	121 (72.0)	<0.001
Abnormal of thyroid function (%)	84 (25.5)	53 (31.5)	0.150
Ischemic heart disease (%)	159 (48.3)	99 (58.9)	0.025
Previous hospitalization for HF (%)	70 (21.3)	60 (100.0)	<0.001
NYHA			
I (%)	1 (0.4)	-	-
II (%)	240 (72.9)	82 (48.8)	<0.05
III (%)	74 (22.5)	73 (43.5)	<0.05
IV (%)	14 (4.3)	13 (7.7)	<0.05
Blood test			
BNP (pmol/L)	373.94±317.58	409.82±370.95	0.074
Cre (μmol/L)	76.17±22.15	78.76±24.00	0.578
eGFR (mL/min/1.73 m ²)	79.56±19.01	74.82±18.91	0.972
UA (μmol/L)	334.96±98.46	353.87±110.97	0.523

ALT (U/L)	21.28±16.15	21.78±22.10	0.493
AST (U/L)	22.38±14.11	21.91±11.22	0.364
Hemoglobin (g/L)	131.64±19.74	129.57±19.12	0.509
K ⁺ (mmol/L)	3.97±0.45	4.06±0.50	0.239
Na ⁺ (mmol/L)	142.55±3.18	142.40±3.22	0.743
Serum glucose (mmol/L)	5.39±2.01	5.60±2.13	0.741
HbA1c (%)	6.23±1.24	6.29±1.01	0.627
TC (mmol/L)	3.97±0.93	3.92±1.00	0.561
TG (mmol/L)	1.29±0.66	1.39±0.83	0.461
LDL-C (mmol/L)	2.46±0.82	2.41±0.84	0.685
HDL-C (mmol/L)	1.15±0.27	1.13±0.31	0.059
Echocardiography			
e' (cm/s)	5.64±1.80	5.17±1.72	0.120
LVMI (g/m)	111.06±28.44	115.20±27.76	0.497
LVED (mm)	46.19±4.52	46.17±4.55	0.628
LAD (mm)	37.17±4.73	39.21±5.66	0.071
RVD (mm)	21.04±4.40	22.53±5.92	0.019
IVST (mm)	10.05±1.22	10.36±1.45	0.003
LVPW (mm)	10.02±1.21	10.26±1.43	0.005
RAD (mm)	47.14±6.14	48.60±7.30	0.001
LVEF (%)	62.08±4.96	61.84±4.76	0.476
E/e'	14.48±5.84	17.69±9.01	<0.001
PAP (mm Hg)	32.07±8.32	35.60±9.79	0.101
Drug therapy			
Beta-blocker (%)	185 (56.2)	113 (67.3)	0.018
ACEI/ARB (%)	121 (36.8)	52 (31.0)	0.197
Spironolactone (%)	125 (38.0)	87 (51.8)	0.003
Loop diuretic (%)	237 (72.0)	131 (78.0)	0.153
CCB (%)	100 (30.4)	60 (35.7)	0.230
Digoxin (%)	8 (2.4)	13 (7.7)	0.005

Antiplatelet drug (%)	182 (55.3)	104 (61.9)	0.160
Anticoagulant drug (%)	263 (79.9)	147 (87.5)	0.036
HMG-CoA reductase inhibitor (%)	241 (73.3)	131 (78.0)	0.251
Intervention therapy			
PCI (%)	48 (14.6)	31 (18.5)	0.265
Radiofrequency ablation (%)	102 (31.0)	39 (23.2)	0.068
ICD (%)	52 (15.8)	20 (11.9)	0.243
CABG (%)	3 (0.9)	4 (2.4)	0.189

HFpEF: heart failure with preserved ejection fraction; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; NYHA, New York Heart Association; Cre, creatinine; eGFR, estimated glomerular filtration rate; UA, uric acid; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TC, cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; LVMI, *Left ventricular mass index*; LVED, Left ventricular end diastolic; LAD, left atrial diameter; RAD, right atrial diameter; RVD, right ventricle diameter; IVST, interventricular septal thickness; LVPW, left ventricular posterior wall thickness; LVEF, left ventricular ejection fraction; E/e', mitral Doppler early velocity/mitral annular early velocity; PAP, pulmonary artery systolic pressure; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blockers; HMG-CoA, β -Hydroxy β -methylglutaryl-CoA; PCI, percutaneous coronary intervention. ICD, implantable cardioverter defibrillators. CABG, coronary artery bypass graft.